Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation
about
Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss.N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts.Acute and subchronic exposure to air particulate matter induces expression of angiotensin and bradykinin-related genes in the lungs and heart: Angiotensin-II type-I receptor as a molecular target of particulate matter exposure.Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.Conserved Amblyomma americanum tick Serpin19, an inhibitor of blood clotting factors Xa and XIa, trypsin and plasmin, has anti-haemostatic functions.Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.GSK-3β/NFAT Signaling Is Involved in Testosterone-Induced Cardiac Myocyte Hypertrophy.Kallikrein-related peptidase 8 is expressed in myocardium and induces cardiac hypertrophy.Myocardial AKT: the omnipresent nexus.Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathwayGene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy.Development of diabetic cardiomyopathy and the kallikrein-kinin system--new insights from B1 and B2 receptor signaling.Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formationTransgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction.Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation.Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.Molecular targets of current and prospective heart failure therapies.Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.Cardiac overexpression of alcohol dehydrogenase exacerbates chronic ethanol ingestion-induced myocardial dysfunction and hypertrophy: role of insulin signaling and ER stress.Increased Age-Related Cardiac Dysfunction in Bradykinin B2 Receptor-Deficient Mice.Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.RhoA/ROCK may involve in cardiac hypertrophy induced by experimental hyperthyroidism.
P2860
Q34328671-8533D604-8CAF-4FA1-882C-680F5C14ECCBQ34554682-E1AF4847-9285-4AFE-B1CF-49CFE1455921Q35786530-A8267E5F-925A-41F2-878C-781A7678D9BAQ35809634-65CCD306-9549-4942-9408-3A71D454195DQ35812375-E8092C59-56C9-4EF8-8894-F732F7E746AFQ35900305-C5C1E628-D9EE-4E63-95A3-1AD17F621999Q36225026-1C6346BA-0337-48D1-B892-46816DB0F683Q36517193-FB553CE0-0DFE-4365-89C3-9C59C70FB359Q36908289-7DB5F7D6-D74A-4E2A-8B61-B3CF15A53A58Q36972964-438C8643-FFEA-4145-AD2E-3C2918AF7303Q37193691-DC6FCF23-A2E0-4720-AB30-49E9778E9833Q37216578-73DA3C87-9460-4C67-9B4F-644DE4039FC1Q37235985-8A308493-A3FD-46F7-9335-9BD3631D3C08Q37340113-81B86ADA-E4D0-4124-AFB7-8AF9BF94DD50Q37344438-23134C15-1364-4DA2-88CE-4045E7A52011Q37697813-62ED1085-CD01-4C05-A597-9D782CE89C9EQ38076688-2A68B5D7-6AF3-4B24-91FE-32313C709FB7Q40070798-6F46E748-BD68-49BA-87EE-53A1A24E5B34Q41467221-19BCB36B-27EC-417C-95F3-2607D67AAD91Q41752395-DED62253-4F90-4D46-8442-1792315D292DQ51441141-AF3E1F9D-F337-48BD-8B40-F5D148B7F508Q54336311-44BAA910-A5E6-458E-84A2-A301B45D76CF
P2860
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3beta activation
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@ast
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@en
type
label
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@ast
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@en
prefLabel
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@ast
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@en
P2093
P2860
P1476
Tissue kallikrein protects aga ...... nthase kinase-3beta activation
@en
P2093
P2860
P304
P356
10.1016/J.CARDIORES.2006.10.014
P577
2006-10-27T00:00:00Z